WG
DNTH icon

Winton Group’s Dianthus Therapeutics DNTH Stock Holding History

Winton Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,238
Closed -$265K – 658
2024
Q2 		$265K Buy
+10,238
New +$246K 0.02% 506

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Winton Group's DNTH Position: Q3 2024 in Review

Winton Group sold out of Dianthus Therapeutics (DNTH) in Q3 2024, closing a stake of 10,238 shares — an estimated $265K sold.

Winton Group first reported a position in DNTH in Q2 2024 and held it in 1 quarter. The position peaked at $265K in Q2 2024. 91 funds tracked by Wall St. Rank hold DNTH as of Q3 2024.

  • Winton Group reported no remaining Dianthus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Winton Group sold 10,238 Dianthus Therapeutics shares in Q3 2024, an estimated $265K.
  • Winton Group first reported a position in Dianthus Therapeutics in Q2 2024 and held it in 1 quarter.
  • Winton Group's Dianthus Therapeutics position peaked at $265K in Q2 2024.
  • 91 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2024.

Based on Winton Group's 13F filing for Q3 2024, filed 12 Nov 2024.